137 related articles for article (PubMed ID: 31676855)
1. Evidence that fodipir (DPDP) binds neurotoxic Pt
Stehr JE; Lundström I; Karlsson JOG
Sci Rep; 2019 Nov; 9(1):15813. PubMed ID: 31676855
[TBL] [Abstract][Full Text] [Related]
2. Manganese- and Platinum-Driven Oxidative and Nitrosative Stress in Oxaliplatin-Associated CIPN with Special Reference to Ca
Karlsson JOG; Jynge P
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673932
[TBL] [Abstract][Full Text] [Related]
3. Mangafodipir trisodium injection, a new contrast medium for magnetic resonance imaging: in vitro metabolism and protein binding studies of the active component MnDPDP in human blood.
Toft KG; Kindberg GM; Skotland T
J Pharm Biomed Anal; 1997 Apr; 15(7):983-8. PubMed ID: 9160265
[TBL] [Abstract][Full Text] [Related]
4. Calmangafodipir [Ca4Mn(DPDP)5], mangafodipir (MnDPDP) and MnPLED with special reference to their SOD mimetic and therapeutic properties.
Karlsson JO; Ignarro LJ; Lundström I; Jynge P; Almén T
Drug Discov Today; 2015 Apr; 20(4):411-21. PubMed ID: 25463039
[TBL] [Abstract][Full Text] [Related]
5. Mangafodipir a Selective Cytoprotectant - with Special Reference to Oxaliplatin and Its Association to Chemotherapy-Induced Peripheral Neuropathy (CIPN).
Karlsson JOG; Andersson RG; Jynge P
Transl Oncol; 2017 Aug; 10(4):641-649. PubMed ID: 28668762
[TBL] [Abstract][Full Text] [Related]
6. Effects of MnDPDP, DPDP--, and MnCl2 on cardiac energy metabolism and manganese accumulation. An experimental study in the isolated perfused rat heart.
Brurok H; Schjøtt J; Berg K; Karlsson JO; Jynge P
Invest Radiol; 1997 Apr; 32(4):205-11. PubMed ID: 9101355
[TBL] [Abstract][Full Text] [Related]
7. Effects of manganese dipyridoxyl diphosphate, dipyridoxyl diphosphate--, and manganese chloride on cardiac function. An experimental study in the Langendorff perfused rat heart.
Brurok H; Schjøtt J; Berg K; Karlsson JO; Jynge P
Invest Radiol; 1995 Mar; 30(3):159-67. PubMed ID: 7797414
[TBL] [Abstract][Full Text] [Related]
8. Mangafodipir as a cardioprotective adjunct to reperfusion therapy: a feasibility study in patients with ST-segment elevation myocardial infarction.
Karlsson JE; El-Saadi W; Ali M; Puskar W; Skogvard P; Engvall JE; Andersson RG; Maret E; Jynge P
Eur Heart J Cardiovasc Pharmacother; 2015 Jan; 1(1):39-45. PubMed ID: 27533964
[TBL] [Abstract][Full Text] [Related]
9. Fodipir and its dephosphorylated derivative dipyridoxyl ethyldiamine are involved in mangafodipir-mediated cytoprotection against 7β-hydroxycholesterol-induced cell death.
Laskar A; Andersson RG; Li W
Pharmacology; 2013; 92(3-4):182-6. PubMed ID: 24080534
[TBL] [Abstract][Full Text] [Related]
10. Superior therapeutic index of calmangafodipir in comparison to mangafodipir as a chemotherapy adjunct.
Karlsson JO; Kurz T; Flechsig S; Näsström J; Andersson RG
Transl Oncol; 2012 Dec; 5(6):492-502. PubMed ID: 23323161
[TBL] [Abstract][Full Text] [Related]
11. Effects of MnDPDP and ICRF-187 on Doxorubicin-Induced Cardiotoxicity and Anticancer Activity.
Kurz T; Grant D; Andersson RG; Towart R; De Cesare M; Karlsson JO
Transl Oncol; 2012 Aug; 5(4):252-9. PubMed ID: 22937177
[TBL] [Abstract][Full Text] [Related]
12. Mangafodipir trisodium injection, a new contrast medium for magnetic resonance imaging: detection and quantitation of the parent compound MnDPDP and metabolites in human plasma by high performance liquid chromatography.
Toft KG; Friisk GA; Skotland T
J Pharm Biomed Anal; 1997 Apr; 15(7):973-81. PubMed ID: 9160264
[TBL] [Abstract][Full Text] [Related]
13. Spectroscopic and metabolic effects of MnCl2 and MnDPDP on the isolated and perfused rat heart.
Vander Elst L; Colet JM; Muller RN
Invest Radiol; 1997 Oct; 32(10):581-8. PubMed ID: 9342116
[TBL] [Abstract][Full Text] [Related]
14. Exacerbated Neuropathy in POLAR A and M Trials Due to Redox Interaction of PledOx-Associated Mn
Karlsson JOG; Jynge P; Ignarro LJ
Antioxidants (Basel); 2023 Mar; 12(3):. PubMed ID: 36978857
[TBL] [Abstract][Full Text] [Related]
15. Manganese dipyridoxyl diphosphate: MRI contrast agent with antioxidative and cardioprotective properties?
Brurok H; Ardenkjaer-Larsen JH; Hansson G; Skarra S; Berg K; Karlsson JO; Laursen I; Jynge P
Biochem Biophys Res Commun; 1999 Jan; 254(3):768-72. PubMed ID: 9920816
[TBL] [Abstract][Full Text] [Related]
16. Mangafodipir (MnDPDP)-and MnCl2-induced endothelium-dependent relaxation in bovine mesenteric arteries.
Asplund A; Grant D; Karlsson JO
J Pharmacol Exp Ther; 1994 Nov; 271(2):609-14. PubMed ID: 7965775
[TBL] [Abstract][Full Text] [Related]
17. May Mangafodipir or Other SOD Mimetics Contribute to Better Care in COVID-19 Patients?
Karlsson JOG; Jynge P; Ignarro LJ
Antioxidants (Basel); 2020 Oct; 9(10):. PubMed ID: 33050459
[TBL] [Abstract][Full Text] [Related]
18. Stability and transmetallation of the magnetic resonance contrast agent MnDPDP measured by EPR.
Schmidt PP; Toft KG; Skotland T; Andersson K
J Biol Inorg Chem; 2002 Mar; 7(3):241-8. PubMed ID: 11935348
[TBL] [Abstract][Full Text] [Related]
19. Myocardial manganese elevation and proton relaxivity enhancement with manganese dipyridoxyl diphosphate. Ex vivo assessments in normally perfused and ischemic guinea pig hearts.
Brurok H; Skoglund T; Berg K; Skarra S; Karlsson JO; Jynge P
NMR Biomed; 1999 Oct; 12(6):364-72. PubMed ID: 10516618
[TBL] [Abstract][Full Text] [Related]
20. Cardiac metal contents after infusions of manganese. An experimental evaluation in the isolated rat heart.
Brurok H; Berg K; Sneen L; Grant D; Karlsson JO; Jynge P
Invest Radiol; 1999 Jul; 34(7):470-6. PubMed ID: 10399637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
